Clinical Report: Immune Microenvironment Dynamics and Resistance to Immunotherapy
Overview
This review explores the complexities of immune checkpoint inhibitor resistance in gastric and gastroesophageal junction adenocarcinoma, emphasizing the role of spatial immune ecology. It highlights the limitations of conventional biomarkers.
Background
Gastric cancer is a leading cause of cancer-related morbidity and mortality globally, with advanced cases often achieving limited durable responses to treatment. The introduction of immune checkpoint inhibitors has transformed therapeutic approaches, yet responses vary significantly among patients. Understanding the immune microenvironment is crucial for improving treatment outcomes.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
Immune checkpoint inhibitors have reshaped treatment for advanced gastric cancer, but durable benefits are inconsistent.
Current biomarkers do not fully account for the ability of antitumor immunity to engage malignant tissues.
Spatial immune-ecology framework categorizes gastric adenocarcinoma into various immune ecosystems.
Key spatial features influencing immunotherapy resistance include CD8+ T cell infiltration and the presence of tertiary lymphoid structures.
Lesion-level biomarker discordance may affect treatment outcomes.
Clinical Implications
Current biomarkers should be complemented with spatial features to better understand patient responses to immunotherapy.
Conclusion
A deeper understanding of the immune microenvironment in gastric cancer is necessary to enhance the efficacy of immunotherapy.
